Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 42 articles:
HTML format
Text format



Single Articles


    April 2017
  1. SANS M, Gharpure KM, Tibshirani R, Zhang J, et al
    Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
    Cancer Res. 2017 Apr 17. pii: canres.3044.2016.
    PubMed     Text format     Abstract available



  2. Correction: EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.
    Cancer Res. 2017;77:2175.
    PubMed     Text format    


  3. WANG L, Shi C, Wright FA, Guo D, et al
    Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.
    Cancer Res. 2017 Apr 10. pii: canres.3119.2016.
    PubMed     Text format     Abstract available


  4. OSE J, Poole EM, Schock H, Lehtinen M, et al
    Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium.
    Cancer Res. 2017 Apr 5. pii: canres.3322.2016.
    PubMed     Text format     Abstract available


    February 2017
  5. CHEN MW, Yang ST, Chien MH, Hua KT, et al
    The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer.
    Cancer Res. 2017 Feb 16. pii: canres.1115.2016.
    PubMed     Text format     Abstract available


  6. SUNDARAM KM, Zhang Y, Mitra AK, Kouadio JK, et al
    Prolactin receptor-mediated internalization of imaging agents detects epithelial ovarian cancer with enhanced sensitivity and specificity.
    Cancer Res. 2017 Feb 15. pii: canres.1454.2016.
    PubMed     Text format     Abstract available


    January 2017
  7. ZHAO L, Ji G, Le X, Wang C, et al
    Long non-coding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer.
    Cancer Res. 2017 Jan 13. pii: canres.1615.2016.
    PubMed     Text format     Abstract available


    November 2016
  8. BAI S, Ingram P, Chen YC, Deng N, et al
    EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.
    Cancer Res. 2016;76:6396-6409.
    PubMed     Text format     Abstract available


  9. YOKOYAMA Y, Zhu H, Lee JH, Kossenkov AV, et al
    BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
    Cancer Res. 2016;76:6320-6330.
    PubMed     Text format     Abstract available


  10. IORIO MV, Croce CM
    Commentary on microRNA Fingerprint in Human Epithelial Ovarian Cancer.
    Cancer Res. 2016;76:6143-6145.
    PubMed     Text format    


    October 2016
  11. KANLIKILICER P, Saber M, Bayraktar R, Mitra R, et al
    Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells.
    Cancer Res. 2016 Oct 14. pii: canres.0714.2016.
    PubMed     Text format     Abstract available


    September 2016
  12. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Text format     Abstract available


  13. JUNG JG, Shih IM, Park JT, Gerry E, et al
    Ovarian cancer chemoresistance relies on the the stem cell reprogramming factor PBX1.
    Cancer Res. 2016 Sep 2. pii: canres.0980.2016.
    PubMed     Text format     Abstract available


    March 2016
  14. REN YA, Mullany LK, Liu Z, Herron AJ, et al
    Mutant p53 promotes epithelial ovarian cancer by regulating tumor differentiation, metastasis, and responsiveness to steroid hormones.
    Cancer Res. 2016 Mar 10. pii: canres.1046.2015.
    PubMed     Text format     Abstract available


    February 2016
  15. HUANG YH, Peng W, Furuuchi N, Gerhart JV, et al
    Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth.
    Cancer Res. 2016 Feb 26. pii: canres.2073.2015.
    PubMed     Text format     Abstract available


    January 2016
  16. POPOVA T, Manie E, Boeva V, Battistella A, et al
    Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications.
    Cancer Res. 2016 Jan 19. pii: canres.2128.2015.
    PubMed     Text format     Abstract available


    December 2015
  17. KANIGEL WINNER K, Steinkamp MP, Lee RJ, Swat M, et al
    Spatial modeling of drug delivery routes for treatment of disseminated ovarian cancer.
    Cancer Res. 2015 Dec 30. pii: canres.1620.2015.
    PubMed     Text format     Abstract available


  18. HILVO M, de Santiago I, Gopalacharyulu P, Schmitt WD, et al
    Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of high-grade serous ovarian carcinomas.
    Cancer Res. 2015 Dec 18. pii: canres.2298.2015.
    PubMed     Text format     Abstract available


  19. ISHIGURO T, Sato A, Ohata H, Ikarashi Y, et al
    Establishment and Characterization of an In Vitro Model of Ovarian Cancer Stem-like Cells with an Enhanced Proliferative Capacity.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  20. PERETS R, Drapkin R
    It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


    November 2015
  21. LIU Y, Metzinger MN, Lewellen KA, Cripps SN, et al
    Obesity Contributes to Ovarian Cancer Metastatic Success through Increased Lipogenesis, Enhanced Vascularity, and Decreased Infiltration of M1 Macrophages.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  22. PENG J, Hamanishi J, Matsumura N, Abiko K, et al
    Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-kappaB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  23. KARYAMPUDI L, Lamichhane P, Krempski J, Kalli KR, et al
    PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-KappaB.
    Cancer Res. 2015 Nov 13. pii: canres.0748.2015.
    PubMed     Text format     Abstract available


    October 2015
  24. MOUGHON D, He H, Schokrpur S, Jiang ZK, et al
    Macrophage Blockade Using CSF1R Inhibitors Reverses The Vascular Leakage Underlying Malignant Ascites In Late-Stage Epithelial Ovarian Cancer.
    Cancer Res. 2015 Oct 15. pii: canres.3373.2014.
    PubMed     Text format     Abstract available


    September 2015
  25. KUHNERT F, Chen G, Coetzee S, Thambi N, et al
    Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  26. TURCOTTE M, Spring K, Pommey S, Chouinard G, et al
    CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
    Cancer Res. 2015 Sep 11. pii: canres.3569.2014.
    PubMed     Text format     Abstract available


  27. HEMACHANDRA LP, Shin DH, Dier U, Iuliano JN, et al
    Mitochondrial superoxide dismutase has a pro-tumorigenic role in ovarian clear cell carcinoma.
    Cancer Res. 2015 Sep 10. pii: canres.3799.2014.
    PubMed     Text format     Abstract available


    August 2015
  28. BAGLEY AF, Scherz-Shouval R, Galie PA, Zhang AQ, et al
    Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors.
    Cancer Res. 2015;75:3255-67.
    PubMed     Text format     Abstract available


  29. GOPINATHAN G, Milagre C, Pearce OM, Reynolds LE, et al
    Interleukin-6 Stimulates Defective Angiogenesis.
    Cancer Res. 2015;75:3098-107.
    PubMed     Text format     Abstract available


    July 2015
  30. BROWNE A, Tookman LA, Ingemarsdotter CK, Bouwman RD, et al
    Pharmacological Inhibition of beta3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.
    Cancer Res. 2015;75:2811-21.
    PubMed     Text format     Abstract available


    June 2015
  31. CHEN P, Huhtinen K, Kaipio K, Mikkonen P, et al
    Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
    Cancer Res. 2015 Jun 29. pii: canres.3242.2014.
    PubMed     Text format     Abstract available


    May 2015
  32. STEWART ML, Tamayo P, Wilson AJ, Wang S, et al
    KRAS genomic status predicts sensitivity to decitabine in an extended assay in ovarian cancer cell lines.
    Cancer Res. 2015 May 12. pii: canres.2860.2014.
    PubMed     Text format     Abstract available


    April 2015
  33. GAJADHAR AS, Johnson H, Slebos RJ, Shaddox K, et al
    Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity.
    Cancer Res. 2015;75:1495-503.
    PubMed     Text format     Abstract available


    February 2015
  34. MILAGRE CS, Gopinathan G, Everitt G, Thompson RG, et al
    Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL-6 antibodies with implications for combined therapy in ovarian cancer.
    Cancer Res. 2015 Feb 10. pii: canres.1801.2014.
    PubMed     Text format     Abstract available


    January 2015
  35. CECCALDI R, O'Connor KW, Mouw KW, Li AY, et al
    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


    November 2014
  36. KOLEV VN, Wright QG, Vidal CM, Ring JE, et al
    PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
    Cancer Res. 2014 Nov 28. pii: canres.1223.2014.
    PubMed     Text format     Abstract available


  37. SALIMIAN B, Caneba C, Nowicka A, Nabiyar AW, et al
    Nitric oxide mediates metabolic coupling of omentum-derived adipose to ovarian and endometrial cancer cells.
    Cancer Res. 2014 Nov 25. pii: canres.1337.2014.
    PubMed     Text format     Abstract available


  38. GALANIS E, Atherton PJ, Maurer MJ, Knutson KL, et al
    Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
    Cancer Res. 2014 Nov 14. pii: canres.2533.2014.
    PubMed     Text format     Abstract available


  39. ROSANO L, Cianfrocca R, Tocci P, Spinella F, et al
    Endothelin A receptor/Beta-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.
    Cancer Res. 2014 Nov 6. pii: canres.3133.2013.
    PubMed     Text format     Abstract available


  40. KASIAPPAN R, Sun Y, Lungchukiet P, Quarni W, et al
    Vitamin D suppresses leptin stimulation of cancer growth through microRNA.
    Cancer Res. 2014;74:6194-204.
    PubMed     Text format     Abstract available


    October 2014
  41. RICCI F, Bizzaro F, Cesca M, Guffanti F, et al
    Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.
    Cancer Res. 2014 Oct 10. pii: canres.0274.2014.
    PubMed     Text format     Abstract available


    August 2014
  42. ZHAO Y, Yang Y, Trovik J, Sun K, et al
    A Novel Wnt Regulatory Axis in Endometrioid Endometrial Cancer.
    Cancer Res. 2014 Aug 1. pii: canres.0427.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: